\documentclass[10pt]{article}

\usepackage{fullpage}
\usepackage{setspace}
\usepackage{parskip}
\usepackage{titlesec}
\usepackage[section]{placeins}
\usepackage{xcolor}
\usepackage{breakcites}
\usepackage{lineno}
\usepackage{hyphenat}





\PassOptionsToPackage{hyphens}{url}
\usepackage[colorlinks = true,
            linkcolor = blue,
            urlcolor  = blue,
            citecolor = blue,
            anchorcolor = blue]{hyperref}
\usepackage{etoolbox}
\makeatletter
\patchcmd\@combinedblfloats{\box\@outputbox}{\unvbox\@outputbox}{}{%
  \errmessage{\noexpand\@combinedblfloats could not be patched}%
}%
\makeatother


\usepackage{natbib}




\renewenvironment{abstract}
  {{\bfseries\noindent{\abstractname}\par\nobreak}\footnotesize}
  {\bigskip}

\titlespacing{\section}{0pt}{*3}{*1}
\titlespacing{\subsection}{0pt}{*2}{*0.5}
\titlespacing{\subsubsection}{0pt}{*1.5}{0pt}


\usepackage{authblk}


\usepackage{graphicx}
\usepackage[space]{grffile}
\usepackage{latexsym}
\usepackage{textcomp}
\usepackage{longtable}
\usepackage{tabulary}
\usepackage{booktabs,array,multirow}
\usepackage{amsfonts,amsmath,amssymb}
\providecommand\citet{\cite}
\providecommand\citep{\cite}
\providecommand\citealt{\cite}
% You can conditionalize code for latexml or normal latex using this.
\newif\iflatexml\latexmlfalse
\providecommand{\tightlist}{\setlength{\itemsep}{0pt}\setlength{\parskip}{0pt}}%

\AtBeginDocument{\DeclareGraphicsExtensions{.pdf,.PDF,.eps,.EPS,.png,.PNG,.tif,.TIF,.jpg,.JPG,.jpeg,.JPEG}}

\usepackage[utf8]{inputenc}
\usepackage[english]{babel}



\usepackage{float}








\begin{document}

\title{Inhibitory role of recombinant neorudin on canine coronary artery
thrombosis}



\author[1]{Yu-bin Liu}%
\author[2]{Xingchen Zhou}%
\author[2]{Yun Liu}%
\author[1]{Lin Zhang}%
\author[1]{Ying Zhou}%
\author[2]{Xiao Xu}%
\author[1]{Can Zheng}%
\author[3]{Zhuan-you Zhao}%
\author[1]{Chu-tse Wu}%
\author[1]{Ji-de Jin}%
\affil[1]{Beijing Institute of Radiation Medicine}%
\affil[2]{Beijing Institute of Radiation Medicine Beijing}%
\affil[3]{Center for Pharmacodynamic Research, Tianjin Institute of Pharmaceutical Reseach}%


\vspace{-1em}



  
  \date{May 28, 2024}


\begingroup
\let\center\flushleft
\let\endcenter\endflushleft
\maketitle
\endgroup





\selectlanguage{english}
\begin{abstract}
The anticoagulant application is an effective treatment modality for
cardiovascular diseases such as coronary heart disease, unstable angina
pectoris, and myocardial infarction. In this study, the antithrombotic
effect of recombinant neorudin (EPR-hirudin, EH) was evaluated using a
canine model of coronary artery thrombosis. A canine model with platelet
thrombosis in the left circumferent branch of the coronary artery was
designed using Folt's method, and the anti-thrombus activity of EH was
investigated. Femoral administration of EH intravenously had a
significant dose-dependent inhibitory effect on canine coronary artery
thrombosis and the effective rates were 66.7\% (P \textless{} 0.05),
83.3\% (P \textless{} 0.05), and 100\% (P \textless{} 0.01) after
injection of 0.3, 1.0, and 3.0 mg/kg EH, respectively. Furthermore, EH
demonstrated lower bleeding, with shorter bleeding time and less
bleeding loss than low molecular weight heparin (LMWH). Under the
similar effect intensity of EH and LMWH (85 IU/kg), the bleeding time of
the EH group at 30 min was shorter, and the blood loss at 30--120 min
was less than that of LMWH (P\textless{}0.05 and
P\textless{}0.05--0.001, respectively). EH had a significant
dose-dependent inhibitory effect in the dose range of 0.3--3.0 mg/kg on
the coronary artery thrombosis and lower bleeding side effects than LMWH
with a similar antithrombosis effect.%
\end{abstract}%



\sloppy




\selectlanguage{english}
\FloatBarrier
\end{document}

